Balchem (BCPC) vs Cabot (CBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Balchem (BCPC) has outperformed Cabot (CBT) over the past year, gaining 17.9% versus a gain of 2.7%. Over five years, CBT leads with a +42.0% price change compared with +10.2% for BCPC. Balchem is the larger company by market cap ($5.30 billion vs $3.89 billion), about 1.4 times the size.
On valuation, Cabot trades at a lower forward P/E (10.8x vs 26.5x for Balchem). Cabot offers the higher dividend yield (2.42% vs 0.58%). Balchem converts more of its revenue into profit, with a net margin of 14.9% versus 8.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCPC | CBT |
|---|---|---|
| Share price | $166.41 | $75.41 |
| Market cap | $5.30B | $3.89B |
| 1-day change | +0.68% | -2.20% |
| YTD return | +8.51% | +13.77% |
| 1-year return | +17.87% | +2.74% |
| 5-year return | +10.23% | +41.99% |
| P/E ratio (TTM) | 32.76 | 21.61 |
| Forward P/E | 26.53 | 10.79 |
| EPS (TTM) | $5.08 | $3.49 |
| Dividend yield | 0.58% | 2.42% |
| Annual dividend | $0.96 | $1.82 |
| Revenue (latest FY) | $1.04B | $3.71B |
| Revenue growth (YoY) | +8.75% | -7.04% |
| Net income (latest FY) | $154.84M | $331.00M |
| Gross margin | 35.74% | 25.32% |
| Operating margin | 20.18% | 16.73% |
| Net margin | 14.93% | 8.91% |
| 52-week high | $183.90 | $94.53 |
| 52-week low | $139.17 | $58.33 |
| Distance from 52-week high | -9.51% | -20.23% |
| Analyst consensus | none | buy |
| Avg. price target upside | +25.74% | +19.79% |
| Average volume | 198.23K | 416.38K |
| Shares outstanding | 31.88M | 51.63M |
| Employees | 1,379 | 4,064 |
| Sector | Industrials | Industrials |
| Industry | Major Chemicals | Major Chemicals |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCPC has outperformed CBT by 15.1 percentage points over the past year.
- Balchem trades at a higher earnings multiple (32.8x vs 21.6x trailing P/E).
- Cabot offers a meaningfully higher dividend yield (2.42% vs 0.58%).
- Balchem is more profitable, keeping 14.9 cents of every revenue dollar as net income versus 8.9 cents for Cabot.
- Balchem grew revenue faster in its latest fiscal year (+8.75% vs -7.04%).
About Balchem
BCPC stock →Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Industrials · Major Chemicals · 1,379 employees
About Cabot
CBT stock →Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through two segments, Reinforcement Materials and Performance Chemicals.
Industrials · Major Chemicals · 4,064 employees
BCPC vs CBT FAQ
Which is bigger, Balchem or Cabot?
Balchem (BCPC) is larger, with a market capitalization of $5.30B compared with $3.89B for Cabot (CBT).
Which stock has performed better over the past year, BCPC or CBT?
BCPC returned +17.87% over the past 12 months, compared with +2.74% for CBT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BCPC or CBT?
CBT has the lower trailing P/E at 21.6, versus 32.8 for BCPC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Balchem or Cabot?
Cabot has the higher yield at 2.42%, compared with 0.58% for Balchem.
Are Balchem and Cabot in the same industry?
Yes. Both are classified in the Major Chemicals industry within the Industrials sector.